- Home
- ZCMD vs CGTX Comparison
ZCMD vs CGTX Comparison
Compare ZCMD & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZCMD | CGTX |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 94.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZCMD | CGTX |
|---|---|---|
| Price | $0.20 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | ★ 4.5M | 941.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.22 |
| 52 Week High | $1.59 | $3.83 |
Technical Indicators
Market Signals| Indicator | ZCMD | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.87 | 43.59 |
| Support Level | $0.19 | $1.05 |
| Resistance Level | $0.23 | $1.19 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 1.45 | 54.43 |
Price Performance
Historical ComparisonAbout ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.